Majeed Syndrome
Majeed syndrome is an extremely rare inherited autoinflammatory disorder defined by a combination of bone inflammation, anemia and skin lesions. It is caused by recessive mutations in the LPIN2 gene, which disrupt the regulation of inflammatory cytokines, particularly interleukin-1 beta (IL-1β).
At Haute-Derma, we approach Majeed syndrome with great care, because it directly affects a child's physical growth and ability to make blood. Our goal is to switch off the chronic bone inflammation to prevent joint deformity while working with hematology to correct the anemia, so that patients can enjoy a stable, healthy quality of life.
Our Approach to Treating Majeed Syndrome
Our team at Haute-Derma focuses on suppressing the systemic inflammation that drives both the bone damage and the bone marrow suppression. We understand that children with Majeed syndrome often live with persistent bone pain and the fatigue of chronic anemia.
We have been early adopters of targeted IL-1 biologic therapy, which brings marked improvement in symptom control and helps normalize blood counts. At Haute-Derma, every patient follows a closely monitored plan, from bone density to complete blood counts, to support the best possible overall development.
Our comprehensive management of Majeed syndrome includes:
- LPIN2 gene sequencing to pinpoint the disease-causing mutation.
- Anti-IL-1 biologic therapy to heal bone lesions and improve anemia.
- Specialist dermatology care for the associated neutrophilic dermatoses.
Diagnosing Majeed Syndrome at Haute-Derma
At Haute-Derma, diagnosis is built around the characteristic triad:
- Chronic recurrent multifocal osteomyelitis (CRMO): Recognizing episodes of deep bone pain and swelling, usually in the long bones, with very early onset (often before age 2).
- Congenital dyserythropoietic anemia (CDA): Assessing anemia caused by defective red blood cell production, which leaves children pale and slow to grow.
- Neutrophilic dermatosis: Looking for Sweet syndrome-like skin lesions or red inflammatory plaques packed with neutrophils.
- Imaging (X-ray/MRI): Detecting the multiple lytic and sclerotic bone lesions typical of CRMO.
- Molecular genetic testing: Identifying the LPIN2 mutation to confirm the diagnosis and distinguish it from other, isolated forms of bone inflammation.
How Is Majeed Syndrome Treated at Haute-Derma?
Our treatment plan aims to shut down the IL-1 storm that damages the bones and bone marrow:
- Anti-IL-1 biologics (anakinra, canakinumab): This is our gold-standard treatment. These drugs not only relieve bone pain but also substantially restore hemoglobin levels.
- Nonsteroidal anti-inflammatory drugs (NSAIDs): Used to relieve pain and help control inflammation during mild flares.
- Specialist hematology support: Monitoring and managing the complications of chronic anemia so that growing organs receive enough oxygen.
- Topical care for skin lesions: Targeted topical treatments from Haute-Derma soothe and quickly heal inflamed, pustular skin.
- Monitoring growth and bone density: Regular assessments help prevent short stature and permanent bone deformities.
